On June 4, 2026, Vanda Pharmaceuticals Inc. held its annual meeting where shareholders elected three directors and ratified the accounting firm PricewaterhouseCoopers for the fiscal year 2026. Significant voting results included 35,242,659 votes for executive compensation approval and 31,729,991 for increasing shares under the 2016 Plan.